[ad_1]
(CercleFinance.com) – Roche announced on Monday that it expected the favorable trajectory recorded in terms of its sales to continue in 2025.
This announcement comes as the Swiss biopharmaceutical group saw its turnover growth jump 9% in the second quarter, beyond the average annual growth of 5% recorded over the last ten years.
On the occasion of its ‘Pharma Day 2024’ being held today in London, the laboratory has set itself the objective of launching 20 ‘transformative’ drugs by 2029 in therapeutic areas with serious societal challenges.
The laboratory has displayed its priorities in 11 diseases, in which it now says it is investing from the beginning to the end of the cycle, namely breast cancer, lung cancer, blood cancers, hemophilia, sclerosis. plaque, Alzheimer’s disease, chronic bowel disease, COPD, ocular hypertension, AMD and obesity.
Anticipating that the share of the world’s population that is overweight or obese will rise from 42% today to 54% in 2035, Roche says it expects the obesity market to surpass the $100 billion mark by 2030.
Concerning the development of new drugs, the group says it expects to reduce the research and development (R&D) costs of new products called ‘NME’ (new molecular entities) by 20% by 2030.
Regarding the entire process, that is to say from the identification of the new molecule to the end of phase III clinical trials, the company is aiming for a 40% reduction in the development time of his new projects until then.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
[ad_2]
Source link -84